FinVector Oy Revenue and Competitors

Claim your profile

Kuopio, Finland



Total Funding



Estimated Revenue & Valuation

  • FinVector Oy's estimated annual revenue is currently $24.3M per year.(i)
  • FinVector Oy's estimated revenue per employee is $201,000

Employee Data

  • FinVector Oy has 121 Employees.(i)
  • FinVector Oy grew their employee count by 30% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

FinVector is the world leader in the research and development of gene and cell therapies. Our state-of-the-art facilities, highly experienced scientific team and commitment to work closely with clients every step of the way, have helped us to build an excellent reputation in the gene therapy market. In addition to our own products, we operate as contract manufacturing organisation to clients' products and help them in their process development. We offer services across a wide range of viral-based product types, including Adenoviral, AAV, and Lentiviral-based vectors. From our cutting-edge fully-licensed GMP manufacturing facility in Finland, we have built an extensive pipeline of gene therapy products and technologies for our clients. Our mission is to improve and extend people's lives by finding solutions in advanced medicines. Moreover, we want to be a company that people aspire to work for. FinVector is based in Kuopio, Finland. We currently employ over 140 employees.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





FinVector Oy News

4-Jul-18 - Welcome to the Kuopio Center for Gene and Cell Therapy

... leading ATMP manufacturer FinVector Oy and gene therapy developer FKD Therapies Oy, located in the same research campus in Kuopio.

26-Apr-18 - Kuopioon tulee uusi kansainvälinen tutkimuskeskus – työllistää 45–50

Säätiö omistaa myös Kuopiossa geeniterapialääkkeitä kehittävän FinVector Oy:n, joka tunnettiin aiemmin nimellä Ark Therapeutics.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding